A promising new approach of VEGFR2-based DNA vaccine for tumor immunotherapy.
OBJECTIVE
To develop new approach for tumor immunotherapy with VEGFR2-based DNA vaccine.


METHODS
VEGFR2 derived from different species were prepared by RT-PCR and subjected to recombinant constructs. The chimeric gene of VEGFR2 was prepared by integrating different epitopes in different species. By transfecting into cells, the immunological effect was evaluated with the approaches of ELISA, ELISPOT, and animal experiments.


RESULTS
(1) All these constructs, in particular chimeric construct, can result in both humoral- and cellular-immune response in BALB/c mice after immunization evaluated by the ratio of CD4+/CD8+ and release of IFN-gamma and IL-4 respectively. (2) Mice were vaccinated with these constructs and challenged with renal carcinoma cells subsequently. It manifested that tumor growth was suppressed significantly in the mice vaccinated by chimeric VEGFR2 construct.


CONCLUSIONS
Our results manifested that VEGFR2-based DNA chimeric vaccine could be developed as a promising approach for tumor immunotherapy.
Yan
Jinqi
J
Institute of Basic Medical Sciences, Academy of Military Medical Sciences, Beijing 100850, China.
Jia
Rui
R
Song
Hongbin
H
Liu
Ying
Y
Zhang
Liang
L
Zhang
Wei
W
Wang
Yu
Y
Zhu
Yunfeng
Y
Yu
Jiyun
J
D000818:Animals; D015153:Blotting, Western; D015496:CD4-Positive T-Lymphocytes / Q000166:cytology / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000166:cytology / Q000276:immunology; D019496:Cancer Vaccines / Q000008:administration & dosage / Q000276:immunology; D002460:Cell Line; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D051379:Mice; D008807:Mice, Inbred BALB C; D009374:Neoplasms, Experimental / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014162:Transfection; D047368:Tumor Burden / Q000276:immunology; D014611:Vaccination; D019444:Vaccines, DNA / Q000008:administration & dosage / Q000276:immunology*; D040301:Vascular Endothelial Growth Factor Receptor-2 / Q000235:genetics / Q000276:immunology* / Q000378:metabolism
D019496:Cancer Vaccines; D019444:Vaccines, DNA; D040301:Vascular Endothelial Growth Factor Receptor-2